Switching to a new weight-loss medicine from tirzepatide
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests how well adults with overweight or obesity, with or without type 2 diabetes, tolerate switching from their current weight-loss medication (tirzepatide) to a new medicine called zenagamtide. It may help you understand if this new option is easier on your stomach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been taking a stable dose of tirzepatide for at least 4 weeks.
- If you have type 2 diabetes, you are on up to two oral diabetes medications (like metformin or SGLT2 inhibitors) and have been on a stable dose for at least 90 days.
- You are not pregnant, breastfeeding, or planning to become pregnant, and if you can get pregnant, you must use effective birth control.
- You have not had to lower your tirzepatide dose because of side effects.
- You are not currently taking any other prescription or over-the-counter medications (with some exceptions like stable use of statins, blood pressure meds, or occasional pain relievers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called zenagamtide for adults with overweight or obesity, with or without type 2 diabetes, who are currently taking semaglutide. The goal is to see how well people tolerate switching from semaglutide to the new treatment.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This study tests a new medication called tirzepatide, given at carefully adjusted doses, to help people with obesity lose weight while reducing unwanted side effects. Tirzepatide is a newer injectable medicine that helps control appetite and blood sugar.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This study tests a weekly injection called tirzepatide in people with type 1 diabetes who are overweight or have obesity. The goal is to see if it helps with blood sugar control and weight loss when added to insulin therapy.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.